Valeant Likely to Restate Results in Wake of Review

Valeant Pharmaceuticals likely needs to restate some of its previous financial results based on the findings of an internal investigation into its business.

from WSJ.com: US Business http://ift.tt/1oy8vCA
via IFTTT